Targeting mTOR to Overcome Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in Non-Small Cell Lung Cancer Cells

Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors

(2012) Song Dong et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

(2010) Alexa B. Turke et al.   CANCER CELL

In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines

(2010) Hua Cheng et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Loss of PTEN Expression by Blocking Nuclear Translocation of EGR1 in Gefitinib-Resistant Lung Cancer Cells Harboring Epidermal Growth Factor Receptor-Activating Mutations

(2010) C. Yamamoto et al.   CANCER RESEARCH

Not all substrates are treated equally: Implications for mTOR, rapamycin-resistance, and cancer therapy

(2010) Andrew Y. Choo et al.   CELL CYCLE

Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia

(2010) I. M. Ghobrial et al.   CLINICAL CANCER RESEARCH

Oncogenic mutant forms of EGFR: Lessons in signal transduction and targets for cancer therapy

(2010) Gur Pines et al.   FEBS LETTERS

Mammalian Target of Rapamycin (mTOR): Conducting the Cellular Signaling Symphony

(2010) Kathryn G. Foster et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer

(2010) Gregory J. Riely   Journal of Thoracic Oncology

Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo

(2010) Didier Roulin et al.   Molecular Cancer

Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors

(2009) J.-C. Soria et al.   ANNALS OF ONCOLOGY

Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)

(2009) Juan M. García-Martínez et al.   BIOCHEMICAL JOURNAL

Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines

(2009) Silvia La Monica et al.   BIOCHEMICAL PHARMACOLOGY

mTOR Complex 2 Is Required for the Development of Prostate Cancer Induced by Pten Loss in Mice

(2009) David A. Guertin et al.   CANCER CELL

Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer

(2009) T. Yamada et al.   CLINICAL CANCER RESEARCH

An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1

(2009) Carson C. Thoreen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition

(2009) M. Breuleux et al.   MOLECULAR CANCER THERAPEUTICS

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Pharmacology of mTOR Inhibition

(2009) D. A. Guertin et al.   Science Signaling

Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2

(2009) Morris E Feldman et al.   PLOS BIOLOGY

Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)

(2008) K Tamura et al.   BRITISH JOURNAL OF CANCER

Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling

(2008) Tsuneo Ikenoue et al.   EMBO JOURNAL

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

(2008) C.-H. Yun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA